PLX Financial Facts
COST OF REVENUES: -4.25MRESEARCH AND DEVELOPMENT EXPENSES, NET: -5.06M
See Full Income Statement
Total liabilities: 85.58M
Total assets: 70.47M
See Full Balance Sheet
Protalix Biotherapeutics, Inc. (PLX) Earnings
|
Expand Research on PLX
| Next EPS Date | 5/8/24 | EPS Growth Rate | N/A |
|---|---|---|---|
| Average EPS % Beat Rate | +11.7% | Revenue Growth Rate | N/A |
| Average % Move 1-Wk after EPS | -3.3% | Normal Earnings Time | Before Open |
| Date | Qtr | EPS | Cons. | Surprise | Revs | Cons. | Gd. | 1-Week % | 1-Day % | Details | |
|---|---|---|---|---|---|---|---|---|---|---|---|
5/10/17  |
Q117 | -$0.48 | N/A | N/A | $2.9M | $679K | N/A |  | | Details | |
| 3/8/16 | Q415 | -$0.29 | N/A | N/A | $4.4M | $3.5M | N/A | | | Details | |
| 8/16/21 |  |
Q221 | -$0.25 | -$0.08 | -$0.17 | $6.43M | $8.3M | N/A | | | Details |
| 2/27/23 | Q422 | -$0.22 | -$0.15 | -$0.07 | $62.89M | $6.12M | N/A | | | Details | |
| 8/7/23 | Q223 | -$0.16 | N/A | N/A | $24.84M | $10.22M | N/A | | | Details | |
| 5/14/21 | |
Q121 | -$0.14 | -$0.17 | +$0.03 | $11.32M | $10.95M | N/A | | | Details |
| 8/10/20 | |
Q220 | -$0.13 | -$0.20 | +$0.07 | $10.97M | $10.87M | N/A | | | Details |
| 11/7/19 | |
Q319 | -$0.13 | -$0.03 | -$0.10 | $12.09M | $11.6M | N/A | | | Details |
